CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® (PER®) will conduct two CME accredited satellite symposia on renal cell carcinoma (RCC) in conjunction with the 2018 American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium this month in San Francisco. The programs, to be held Feb. 8-9, will feature on-site faculty to discuss the latest innovations in RCC treatment and management.
“The treatment of renal cell carcinoma has advanced tremendously over the past few years and we are thrilled to host two different programs on both adjuvant and advanced treatments and the various factors that go into decision making,” said Phil Talamo, president of PER®. “The two comprehensive programs aim to help clinicians better treat patients with renal cell carcinoma.”
Both activities will be chaired by Robert A. Figlin, M.D., FACP, Steven Spielberg Family Chair in Hematology-Oncology, professor of medicine and biomedical sciences, director of the division of hematology/ oncology, deputy director of Integrated Oncology Service Line, deputy director of Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, in Los Angles, who will be joined by an expert faculty to offer comprehensive discussion on new data regarding emerging RCC research.
The PER® satellite symposia are as follows:
- ASCO GU: Emerging Paradigm Shifts in Renal Cell Carcinoma: A Critical Assessment of Adjuvant Treatment Data, will be held on Feb. 8 at 6:30 p.m. at the Marriott Marquis, San Francisco in room Golden Gate A. The activity will offer an in-depth critical review of adjuvant RCC therapy. Featured faculty will also address audience concerns and questions during a robust Medical Crossfire®. To register, visit www.gotoper.com/conferences/gu18/meetings/emerging-paradigm-shifts-in-renal-cell-carcinoma-a-critical-assessment-of-adjuvant-treatment-data.
- ASCO GU: Personalized Assessment in Advanced RCC Decision Making: Leveraging the Evidence and Patient Characteristics to Inform Decisions Along the Disease Continuum, will be held on Feb. 9 at 7 p.m. at the Marriott Marquis, San Francisco in room Golden Gate A. This case-based, interactive and educational symposium will share evidence-based strategies designed to treat patients with renal cell carcinoma. Faculty will also discuss the rationale for sequencing based on patient characteristics, the future of RCC therapy, and case challenges. To register, visit www.gotoper.com/conferences/asco18rcc/meetings/personalized-assessment-in-advanced-rcc-decision-making-leveraging-the-evidence-and-patient-characteristics-to-inform-decisions-along-the-disease-continuum.
About PER®:
Since 1995, Physicians’ Education Resource, LLC® (PER®), has been the leading provider of live and online CME activities on oncology and hematology by providing high-quality, evidence-based activities featuring leading experts who focus on the application of practice-changing advances. In 2018, PER ® will develop and implement 20 historic annual legacy conferences in the United States and Europe, along with many world-renowned online learning formats such as Medical Crossfire®. PER® is accredited by both the Accreditation Council for Continuing Medical Education (ACCME) and the California Board of Registered Nursing (CBRN). PER® is part of the Cranbury, New Jersey-based Michael J. Hennessy Associates, Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.
